Literature DB >> 1438243

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

C Wild1, T Oas, C McDanal, D Bolognesi, T Matthews.   

Abstract

A peptide designated DP-107 was synthesized containing amino acid residues 558-595 of the envelope glycoprotein gp160 of human immunodeficiency virus type 1 strain LAI (HIV-1LAI). Algorithms for secondary structure have predicted that this region of the envelope transmembrane protein should form an extended alpha-helix. Consistent with this prediction, analysis by circular dichroism (CD) indicated that, under physiological conditions, DP-107 is approximately 85% helical. The high degree of stable secondary structure in a synthetic peptide of this size suggests self-association typical of a coiled coil or leucine zipper. In biological assays, the peptide efficiently blocked virus-mediated cell-cell fusion processes as well as infection of peripheral blood mononuclear cells by both prototypic and primary isolates of HIV-1. A single amino acid substitution in the peptide greatly destabilized its solution structure as measured by CD and abrogated its antiviral activity. An analogue containing a terminal cysteine was oxidized to form a dimer, and this modification lowered the dose required for antiviral effect from 5 to about 1 microgram/ml. These results suggest that both oligomerization and ordered structure are necessary for biological activity. They provide insights also into the role of this region in HIV infection and the potential for development of a new class of antiviral agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1438243      PMCID: PMC50374          DOI: 10.1073/pnas.89.21.10537

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.

Authors:  T J Matthews; K J Weinhold; H K Lyerly; A J Langlois; H Wigzell; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

2.  A general model for the transmembrane proteins of HIV and other retroviruses.

Authors:  W R Gallaher; J M Ball; R F Garry; M C Griffin; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1989-08       Impact factor: 2.205

3.  Antibodies to a putative HIV gp41 immunosuppressive peptide, pHIVIS (583-599), do not correlate significantly with outcome in HIV infection.

Authors:  R Cheingsong-Popov; C Panagiotidi; K Caun; P J Klasse; R Pipkorn; J Blomberg; J Weber
Journal:  AIDS       Date:  1990-03       Impact factor: 4.177

4.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Mapping the anatomy of the immunodominant domain of the human immunodeficiency virus gp41 transmembrane protein: peptide conformation analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy.

Authors:  M B Oldstone; A Tishon; H Lewicki; H J Dyson; V A Feher; N Assa-Munt; P E Wright
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

7.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.

Authors:  C F Ebenbichler; N M Thielens; R Vornhagen; P Marschang; G J Arlaud; M P Dierich
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

9.  Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation.

Authors:  G J Cianciolo; H Bogerd; R Snyderman
Journal:  Immunol Lett       Date:  1988-09       Impact factor: 3.685

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  195 in total

1.  Computational design of D-peptide inhibitors of hepatitis delta antigen dimerization.

Authors:  C D Elkin; H J Zuccola; J M Hogle; D Joseph-McCarthy
Journal:  J Comput Aided Mol Des       Date:  2000-11       Impact factor: 3.686

2.  The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil.

Authors:  J M Matthews; T F Young; S P Tucker; J P Mackay
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Functional importance of the coiled-coil of the Ebola virus glycoprotein.

Authors:  S Watanabe; A Takada; T Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.

Authors:  D M Eckert; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

5.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.

Authors:  T Pierson; T L Hoffman; J Blankson; D Finzi; K Chadwick; J B Margolick; C Buck; J D Siliciano; R W Doms; R F Siliciano
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange.

Authors:  Nichole Cerutti; Barry V Mendelow; Grant B Napier; Maria A Papathanasopoulos; Mark Killick; Makobetsa Khati; Wendy Stevens; Alexio Capovilla
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

8.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.

Authors:  Lifeng Cai; Chungen Pan; Liang Xu; Yuan Shui; Keliang Liu; Shibo Jiang
Journal:  FASEB J       Date:  2011-11-15       Impact factor: 5.191

Review 10.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.